{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T11:14:44Z","timestamp":1791630884820,"version":"4.3.4"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH Clinical and Translational Science","award":["UM1TR0045906"],"award-info":[{"award-number":["UM1TR0045906"]}]},{"name":"NIH Clinical and Translational Science","award":["1UL1 TR003167"],"award-info":[{"award-number":["1UL1 TR003167"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bevacizumab and temsirolimus target angiogenic and mTOR pathways in cancer progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This phase I study enrolled 48 heavily pretreated patients with advanced solid tumors, including an ovarian cancer expansion cohort. Patients received bevacizumab biweekly plus temsirolimus weekly in a 3\u2009+\u20093 design to assess safety, maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs). Exploratory analyses included tumor genomic profiling and dynamic contrast-enhanced MRI (DCE-MRI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients had a median age of 59 and median four prior therapies. Common tumor types were ovarian (27%) and head and neck (15%). Treatment-related adverse events occurred in 93.8%, with 31.3% \u2265grade 3. Five patients experienced DLTs, including grade 3 enteritis, fatigue, bowel obstruction\/abdominal ileus\/pulmonary embolism, bowel perforation and grade 3\/4 elevated liver enzymes. MTD was bevacizumab 10\u2009mg\/kg biweekly plus temsirolimus 20\u2009mg weekly. Overall, objective response rate (ORR) was 7.3% and 19.5% achieved stable disease \u22656\u2009months (clinical benefit rate [CBR] 26.8%). In ovarian cohort, ORR was 16.7% and CBR 33.3%. Patients with tumor regression on DCE-MRI had lower \u0394Ktrans values.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Combination therapy showed acceptable safety and modest activity. Molecular and imaging findings were exploratory and limited. These preliminary observations could inform future biomarker studies. (ClinicalTrials.gov Identifier: NCT01552434)<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf413","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T13:13:35Z","timestamp":1765458815000},"source":"Crossref","is-referenced-by-count":1,"title":["Phase I study of bevacizumab and temsirolimus combination therapy in advanced malignancies: safety, efficacy, and ovarian cancer expansion"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9455-1660","authenticated-orcid":false,"given":"Sarina A","family":"Piha-Paul","sequence":"first","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center , Houston, TX, 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieh","family":"Tseng","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center , Houston, TX, 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Thompson","sequence":"additional","affiliation":[{"name":"Department of Imaging Physics, Division of Diagnostic Imaging, University of Texas MD Anderson Cancer Center , Houston, TX, 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R Jason","family":"Stafford","sequence":"additional","affiliation":[{"name":"Department of Imaging Physics, Division of Diagnostic Imaging, University of Texas MD Anderson Cancer Center , Houston, TX, 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung","family":"Le","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center , Houston, TX, 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center , Houston, TX, 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1933-0419","authenticated-orcid":false,"given":"Siqing","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center , Houston, TX, 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2713-233X","authenticated-orcid":false,"given":"Apostolia","family":"Tsimberidou","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center , Houston, TX, 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Blumenschein","sequence":"additional","affiliation":[{"name":"Department of Thoracic and Head and Neck Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center , Houston, TX, 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi Rodon","family":"Ahnert","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center , Houston, TX, 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M","family":"Slopis","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center , Houston, TX, 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center , Houston, TX, 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aung","family":"Naing","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center , Houston, TX, 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6816-6072","authenticated-orcid":false,"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center , Houston, TX, 77030,","place":["United States"]},{"name":"The Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, University of Texas MD Anderson Cancer Center , Houston, TX, 77030,","place":["United States"]},{"name":"Department of Breast Surgical Oncology, Division of Surgery, University of Texas MD Anderson Cancer Center , Houston, TX, 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaan S","family":"Ng","sequence":"additional","affiliation":[{"name":"Department of Abdominal Imaging, Division of Diagnostic Imaging, University of Texas MD Anderson Cancer Center , Houston, TX, 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Westin","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, University of Texas MD Anderson Cancer Center , Houston, TX, 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil K","family":"Sood","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, University of Texas MD Anderson Cancer Center , Houston, TX, 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,13]]},"reference":[{"key":"2026021302361983500_oyaf413-B1","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.18632\/oncotarget.1834","article-title":"Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus","volume":"5","author":"Piha-Paul","year":"2014","journal-title":"Oncotarget"},{"key":"2026021302361983500_oyaf413-B2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1053\/j.seminoncol.2003.08.013","article-title":"A phase I\/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer","volume":"30","author":"Cobleigh","year":"2003","journal-title":"Semin Oncol"},{"key":"2026021302361983500_oyaf413-B3","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1200\/JCO.2004.08.116","article-title":"Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer","volume":"22","author":"Raymond","year":"2004","journal-title":"J Clin Oncol"},{"key":"2026021302361983500_oyaf413-B4","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00280-014-2668-5","article-title":"Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study","volume":"75","author":"Merchan","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026021302361983500_oyaf413-B5","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s10637-014-0169-3","article-title":"A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma","volume":"33","author":"Knox","year":"2015","journal-title":"Invest New Drugs"},{"key":"2026021302361983500_oyaf413-B6","doi-asserted-by":"publisher","first-page":"e220301","DOI":"10.1530\/ERC-22-0301","article-title":"A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors","volume":"30","author":"Abuzakhm","year":"2023","journal-title":"Endocr Relat Cancer"},{"key":"2026021302361983500_oyaf413-B7","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1093\/oncolo\/oyad158","article-title":"A phase I trial of bevacizumab and temsirolimus in combination with valproic acid in advanced solid tumors","volume":"28","author":"Nelson","year":"2023","journal-title":"Oncologist"},{"key":"2026021302361983500_oyaf413-B8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ygyno.2012.12.022","article-title":"Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study","volume":"129","author":"Alvarez","year":"2013","journal-title":"Gynecol Oncol"},{"key":"2026021302361983500_oyaf413-B9","first-page":"1657","article-title":"Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme","volume":"33","author":"Lassen","year":"2013","journal-title":"Anticancer Res"},{"key":"2026021302361983500_oyaf413-B10","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1200\/JCO.2013.50.5305","article-title":"Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial","volume":"32","author":"Rini","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026021302361983500_oyaf413-B11","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2307\/2531693","article-title":"Design and analysis of phase I clinical trials","volume":"45","author":"Storer","year":"1989","journal-title":"Biometrics"},{"key":"2026021302361983500_oyaf413-B12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"2026021302361983500_oyaf413-B13","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1200\/JCO.2006.07.3049","article-title":"Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria","volume":"25","author":"Choi","year":"2007","journal-title":"J Clin Oncol"},{"key":"2026021302361983500_oyaf413-B14","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/j.drudis.2015.05.013","article-title":"The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform","volume":"20","author":"Johnson","year":"2015","journal-title":"Drug Discov Today"},{"key":"2026021302361983500_oyaf413-B15","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1200\/JCO.2014.56.2082","article-title":"Multicenter phase II trial of temsirolimus and bevacizumab in pancreatic neuroendocrine tumors","volume":"33","author":"Hobday","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026021302361983500_oyaf413-B16","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1470-2045(11)70124-3","article-title":"Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial","volume":"12","author":"Negrier","year":"2011","journal-title":"Lancet Oncol"},{"key":"2026021302361983500_oyaf413-B17","doi-asserted-by":"publisher","first-page":"5755","DOI":"10.1158\/1078-0432.CCR-06-0118","article-title":"A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer","volume":"12","author":"Hidalgo","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2026021302361983500_oyaf413-B18","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"key":"2026021302361983500_oyaf413-B19","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3390\/genes11070719","article-title":"PTEN alterations and their role in cancer management: are we making headway on precision medicine?","volume":"11","author":"Fusco","year":"2020","journal-title":"Genes (Basel)"},{"key":"2026021302361983500_oyaf413-B20","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1056\/NEJMra0706596","article-title":"Tumor angiogenesis","volume":"358","author":"Kerbel","year":"2008","journal-title":"N Engl J Med"},{"key":"2026021302361983500_oyaf413-B21","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nrclinonc.2010.47","article-title":"Imaging ovarian cancer and peritoneal metastases\u2014current and emerging techniques","volume":"7","author":"Kyriazi","year":"2010","journal-title":"Nat Rev Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf413\/65877893\/oyaf413.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/3\/oyaf413\/65877893\/oyaf413.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/3\/oyaf413\/65877893\/oyaf413.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T07:36:25Z","timestamp":1770968185000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf413\/8379611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,13]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,5]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf413","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,12,13]]},"article-number":"oyaf413"}}